RedHill Biopharma (RDHL) Operating Expenses (2012 - 2023)

RedHill Biopharma (RDHL) has 12 years of Operating Expenses data on file, last reported at $4.8 million in Q2 2023.

• On a quarterly basis, Operating Expenses fell 48.2% year-over-year to $4.8 million in Q2 2023; TTM through Dec 2024 was $4.8 million, a 75.21% decrease from a year earlier, with the FY2025 full-year figure at $8.2 million, up 26.56% from the prior year.
• Operating Expenses for Q2 2023 stood at $4.8 million, down from $6.9 million in the prior quarter.
• Over the last five years, Operating Expenses for RDHL reached as high as $20.6 million in Q2 2021 and fell as low as $4.8 million in Q2 2023.
• Historically, Operating Expenses has averaged $10.0 million across 5 years, with a median of $9.2 million in 2020.
• Across the five-year window, Operating Expenses jumped 122.37% in 2021 and slumped 55.08% in 2022, its largest moves.
• Year by year, Operating Expenses stood at $6.4 million in 2019, then surged by 112.48% to $13.6 million in 2020, then declined by 8.43% to $12.5 million in 2021, then sank by 38.78% to $7.6 million in 2022, then sank by 37.31% to $4.8 million in 2023.
• Per Business Quant data, the three most recent Operating Expenses figures were $4.8 million in Q2 2023, $6.9 million in Q1 2023, and $7.6 million in Q4 2022.